AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$CYTK

Blum Robert I sold $471K of CYTK

Blum Robert I (President & CEO) sold 7,500 shares of CYTOKINETICS INC (CYTK) at $62.81 ($0.47M total) on 2026-11-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Blum Robert I
Published Nov 2, 2026, 11:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 11:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CYTK
Bearish
medium confidence
Mentioned
$CYTK
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CYTKBearishLow
01

Why it matters

While the sale is modest, it provides a data point for assessing insider sentiment.

02

Market read

The filing is a primary source of new information but its material impact is limited.

03

What to watch

Potential upcoming clinical data releases that may offset sell pressure.

Relevance 3/10Novelty 3/10Timing: after market close on 2026-11-02

Background

Form 4 filings disclose insider transactions; investors monitor them for signals.

Company-level read

Ticker impact

$CYTKBearishMedium confidence
Context

CEO Robert Blum sold 7,500 CYTK shares for $471,075 via a 10b5‑1 plan.

Expected impact

likely downward pressure as the market prices the insider sell.

Evidence & confidence

A $471k sale by the CEO signals potential lack of confidence; size is modest but enough to affect liquidity.

Market effects

Sector

Minimal impact on the biotech sector; insider sales are routine.

Regional

No broader regional effect.

Global

Limited to CYTK shareholders.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to fundamentals.

Key entities

  • person
    Robert Blum

    President & CEO of CytoKinetics Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CYTK insider trading history →

Related articles

$CYTKMedAI 8/10

Cytokinetics Q3 Earnings Call Highlights

Cytokinetics reported Q3 revenue of $47.6M, up from $1.9M YoY, driven by MYQORZO sales. Net loss narrowed to $190.1M. Aficamten met primary endpoints in Phase 3 trial, with EU submission planned for 2027. Company reaffirmed 2026 expense guidance and discussed pipeline milestones.

finance.yahoo.com
$CYTKMedAI 8/10

Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update

CYTOKINETICS INC (CYTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update MYQORZO ® (aficamten) Net Product Revenue of $44.5 Million Expect to Submit Supplemental NDA for Aficamten in Non-Obstructive HCM in Q4 2026 and Type II Variation in the European U

SEC EDGAR 8-K